Close Menu

NEW YORK – Cancer genetics testing lab firm NeoGenomics said on Wednesday that it has acquired Trapelo Health for $65 million, consisting of $35 million in cash on hand and $30 million in NeoGenomics' common stock.

Fort Myers, Florida-based NeoGenomics will offer Burlington, Massachusetts-based Trapelo's clinical decision support system to providers, payors, and labs to aid precision oncology across all healthcare settings.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jun
08
Sponsored by
Qiagen

Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.